User:Mr. Ibrahem/Cariprazine

From Wikipedia, the free encyclopedia
Mr. Ibrahem/Cariprazine
Clinical data
Pronunciation/kəˌripˈrəziːn/
Trade namesVraylar (US), Reagila (EU)
Other namesRGH-188
AHFS/Drugs.comMonograph
Pregnancy
category
  • AU: D
Routes of
administration		By mouth (capsules)
Drug classAtypical antipsychotic[1]
Legal status
Legal status
Pharmacokinetic data
BioavailabilityHigh
Protein binding91–97%
MetabolismLiver via CYP3A4 and to a lesser extent CYP2D6
MetabolitesDesmethylcariprazine
Elimination half-life2–5 days (2–3 wks for active metabolite, desmethylcariprazine)
ExcretionUrine (21%), bile
Identifiers
  • N'-[trans-4-[2-[4-(2,3-Dichlorophenyl)-1-piperazinyl]ethyl]cyclohexyl]-N,N-dimethylurea
Chemical and physical data
FormulaC21H32Cl2N4O
Molar mass427.41 g·mol−1
3D model (JSmol)
  • CN(C)C(=O)N[C@H]1CC[C@H](CCN2CCN(CC2)c2cccc(Cl)c2Cl)CC1
  • InChI=1S/C21H32Cl2N4O/c1-25(2)21(28)24-17-8-6-16(7-9-17)10-11-26-12-14-27(15-13-26)19-5-3-4-18(22)20(19)23/h3-5,16-17H,6-15H2,1-2H3,(H,24,28)/t16-,17- checkY
  • Key:KPWSJANDNDDRMB-QAQDUYKDSA-N checkY

Cariprazine, sold under the brand names Vraylar and Reagila, is an atypical antipsychotic used to treat schizophrenia and bipolar disorder.[5] It is taken by mouth.[5] Use is not recommended by Wales.[6]

Common side effects include movement disorders, heart burn, sleepiness, and restlessness.[5] Other side effects may include neuroleptic malignant syndrome, tardive dyskinesia, diabetes, weight gain, low white blood cells, low blood pressure with standing, and seizures.[5] Use in older people with dementia increase the risk of death.[5] Safety in pregnancy is unclear.[1] It acts primarily on dopamine and serotonin receptors.[7]

Cariprazine was approved for medical use in the United States in 2015 and Europe in 2017.[5][7] In the United Kingdom 4 weeks of treatment costs the NHS about £80 as of 2021.[6] This amount in the United States costs about 1,250 USD.[8]

References[edit]

  1. ^ a b "Cariprazine Monograph for Professionals". Drugs.com. Archived from the original on 21 January 2021. Retrieved 30 December 2021.
  2. ^ "Reagila 1.5 mg hard capsules - Summary of Product Characteristics (SmPC)". (emc). 9 August 2018. Archived from the original on 21 October 2020. Retrieved 20 October 2020.
  3. ^ "Vraylar- cariprazine capsule, gelatin coated Vraylar- cariprazine kit". DailyMed. 18 May 2019. Archived from the original on 24 October 2020. Retrieved 20 October 2020.
  4. ^ "Reagila EPAR". European Medicines Agency (EMA). Archived from the original on 24 October 2020. Retrieved 20 October 2020.
  5. ^ a b c d e f g h i "DailyMed - VRAYLAR- cariprazine capsule, gelatin coated". dailymed.nlm.nih.gov. Archived from the original on 11 January 2022. Retrieved 30 December 2021.
  6. ^ a b BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 416. ISBN 978-0857114105.
  7. ^ a b "Reagila". Archived from the original on 24 October 2020. Retrieved 30 December 2021.
  8. ^ "Cariprazine Prices, Coupons & Savings Tips - GoodRx". GoodRx. Retrieved 30 December 2021.
Retrieved from "https://en.wikipedia.org/w/index.php?title=User:Mr._Ibrahem/Cariprazine&oldid=1221240837"